Literature DB >> 14709862

Recent developments in the maytansinoid antitumor agents.

John M Cassady1, Kenneth K Chan, Heinz G Floss, Eckhard Leistner.   

Abstract

Maytansine and its congeners have been isolated from higher plants, mosses and from an Actinomycete, Actinosynnema pretiosum. Many of these compounds are antitumor agents of extraordinary potency, yet phase II clinical trials with maytansine proved disappointing. The chemistry and biology of maytansinoids has been reviewed repeatedly in the late 1970s and early 1980s; the present review covers new developments in this field during the last two decades. These include the use of maytansinoids as "warheads" in tumor-specific antibodies, preliminary metabolism studies, investigations of their biosynthesis at the biochemical and genetic level, and ecological issues related to the occurrence of such typical microbial metabolites in higher plants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709862     DOI: 10.1248/cpb.52.1

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  50 in total

Review 1.  Potential of plant-derived natural products in the treatment of leukemia and lymphoma.

Authors:  David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

2.  Cyclization of synthetic seco-proansamitocins to ansamitocin macrolactams by Actinosynnema pretiosum as biocatalyst.

Authors:  Kirsten Harmrolfs; Marco Brünjes; Gerald Dräger; Heinz G Floss; Florenz Sasse; Florian Taft; Andreas Kirschning
Journal:  Chembiochem       Date:  2010-12-10       Impact factor: 3.164

3.  Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.

Authors:  Lintao Wang; Godfrey Amphlett; Walter A Blättler; John M Lambert; Wei Zhang
Journal:  Protein Sci       Date:  2005-08-04       Impact factor: 6.725

Review 4.  Combinatorial biosynthesis--potential and problems.

Authors:  Heinz G Floss
Journal:  J Biotechnol       Date:  2006-01-18       Impact factor: 3.307

5.  Selective isolation and ansamycin-targeted screenings of commensal actinomycetes from the "maytansinoids-producing" arboreal Trewia nudiflora.

Authors:  Na Zhu; Peiji Zhao; Yuemao Shen
Journal:  Curr Microbiol       Date:  2008-10-25       Impact factor: 2.188

6.  Complete Genome Sequence of Actinosynnema pretiosum X47, An Industrial Strain that Produces the Antibiotic Ansamitocin AP-3.

Authors:  Chuanqing Zhong; Gongli Zong; Shulan Qian; Meng Liu; Jiafang Fu; Peipei Zhang; Jun Li; Guangxiang Cao
Journal:  Curr Microbiol       Date:  2018-06-01       Impact factor: 2.188

7.  Enhancement of ansamitocin P-3 production in Actinosynnema pretiosum by a synergistic effect of glycerol and glucose.

Authors:  Yang Gao; Yuxiang Fan; Komi Nambou; Liujing Wei; Zhijie Liu; Tadayuki Imanaka; Qiang Hua
Journal:  J Ind Microbiol Biotechnol       Date:  2013-10-31       Impact factor: 3.346

8.  The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Authors:  Hernan Carol; Barbara Szymanska; Kathryn Evans; Ingrid Boehm; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2013-02-20       Impact factor: 12.531

9.  Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum.

Authors:  Daniel Ng; Hing Kah Chin; Victor Vai Tak Wong
Journal:  J Ind Microbiol Biotechnol       Date:  2009-07-16       Impact factor: 3.346

10.  Biosynthesis and accumulation of ergoline alkaloids in a mutualistic association between Ipomoea asarifolia (Convolvulaceae) and a clavicipitalean fungus.

Authors:  Anne Markert; Nicola Steffan; Kerstin Ploss; Sabine Hellwig; Ulrike Steiner; Christel Drewke; Shu-Ming Li; Wilhelm Boland; Eckhard Leistner
Journal:  Plant Physiol       Date:  2008-03-14       Impact factor: 8.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.